Medicines & drug development

Which drugs are most suitable for which patient? Which combinations of drugs work best? Can drugs be more afforable? Read about our latest activities and insights here,

October 24, 2024
Phase Two results with CRISPR-Cas9 gene editing support further development as treatment for hereditary angioedema A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful and sudden onset of swelling, sometimes resulting in death. Confirming the findings published earlier this year from researchers from Amsterdam UMC, the University of Auckland and Cambridge University Hospitals NHS Foundation Trust. This phase two study is published today in the New England Journal of Medicine and presented at American College of Allergy, Asthma & Immunology's annual congress on the 26th of October.
- Immunity & vaccination
- Medicines & drug development
March 22, 2024
€9.5M Accelerates Medicines and Vaccines Development for Infectious Diseases Amsterdam UMC, Leiden University Medical Center (LUMC), Radboudumc, Utrecht UMC, and the Centre for Human Drug Research (CHDR) have secured a €9.5 million startup grant from ZonMw to launch a Dutch facility for early clinical research on drugs and vaccines targeting infectious diseases. Professor Hovius, director of the Amsterdam Institute for Immunology & Infectious Diseases (AII), is involved in the initiative.
- Medicines & drug development
February 1, 2024
Gene-editing offers hope for people with hereditary disorder A group of patients with a hereditary disorder have had their lives transformed by a single treatment of a breakthrough gene-editing therapy, according to the lead researcher.
- Medicines & drug development
July 13, 2023
New drug application doubles rates of remission in patients with Ulcerative Colitis A new drug, investigated by Amsterdam UMC together with colleagues around the world in universities and the industry, is effective as a treatment against ulcerative colitis.
- Medicines & drug development
May 11, 2023
Combination therapy outperforms chemotherapy in patients with chronic lymphocytic leukaemia Chemotherapy has been the most effective treatment to date for young and fit patients with chronic lymphocytic leukaemia (CLL). The disease is the most common form of leukaemia in the Western world, causing a substantial health burden on patients and society. It is currently incurable. Research led by researchers from Cologne University, Amsterdam UMC and Copenhagen University, now shows that a chemofree drug-combination therapy is more effective and produces fewer side effects. The results of this study are published today in the New England Journal of Medicine.
February 22, 2023
The Methotrexate Monitoring trial Renske Hebing was awarded the AII Extension Grant in 2021 for her research proposal “Pharmacokinetics of Oral and Subcutaneous Methotrexate in Red and White Blood Cells in Patients with Early Rheumatoid Arthritis – the Methotrexate Monitoring Trial (MeMo study)”. Recently, Renske’s article was published in the Annals of the Rheumatic Diseases (ARD).
- Medicines & drug development
October 24, 2022
Grant awarded: clinical trial anti-inflammatory drug for Sjögren's syndrome A grant of 200,000 euros has been awarded to Dr. Derk Jan Jager and colleagues to set up a study on the safety and efficacy of a drug (AZD9056) for patients with Sjögren’s syndrome. This study will examine whether the drug is able to preserve the function of the salivary glands in patients with Sjögren's syndrome.
- Medicines & drug development
May 30, 2022
Winning combination of drugs for treating Chronic Lymphocytic Leukemia Patients with Chronic Lymphocytic Leukemia (CLL) are better off with a combination of ibrutinib and venetoclax. This is more effective than the standard treatment, researchers of Amsterdam UMC discovered.
November 26, 2021
Good Use of Medicines grant for research group of Jeroen Hermanides The grant will be used to investigate the use of SGLT-2 inhibitors in cardiac surgery.
- Awards, grants & gifts
- Medicines & drug development

Medicines & drug development

We use cookies